All In Biotech

Drug Trial Radar · NCT05492578

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,856

Actual

Start

Aug 22, 2022

Primary completion

Jan 22, 2029

Study completion Jan 22, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Aug 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate to severe atopic dermatitis. The purpose of this study is to characterize the safety and efficacy of amlitelimab in treated participants with moderate to severe atopic dermatitis (AD) who have previously been enrolled in an amlitelimab clinical trial. All participants will have visits during the treatment period every 4 weeks. Responder participants rolling over from EFC17599 and EFC17600, and responder participants enrolling through screening from DRI17366 will be initiated into drug withdrawal (with no drug administration) at LTS17367 baseline visit to monitor durability of treatment response. If these responder participants relapse during LTS17367, they will have treatment restored. Non-responder participants rolling over from EFC17599 or EFC17600, and non-responder participants enrolling through screening from DRI17366 will have treatment administration from LTS17367 baseline. Participants rolling over from DRI17366, SFY17915 and INT18404 will also have treatment administration from LTS17367 baseline. Remote visits with home dosing are allowed for the purpose of study drug administration, when applicable. In the case of remote visit with home dosing, the participant or a caregiver may administer study drug after appropriate training. Alternatively, if needed, and based on the investigator's judgement, home visits with healthcare professional assistance or on-site study drug administration visits can be performed. Where participants discontinue amlitelimab permanently during LTS17367, safety follow up will be performed for a minimum of 140 days from the last amlitelimab administration.

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

  • Topical corticosteroidsDrug

    Pharmaceutical form: Topical Route of administration: Topical

  • Topical calcineurin inhibitorsDrug

    Pharmaceutical form: Topical Route of administration: Topical

  • Oral corticosteroidsDrug

    Pharmaceutical form: Oral Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who experienced treatment-emergent adverse event (TEAE)Time frame: Baseline to Week 332

Locations

392 sites in 29 countries. Site status is shown where the registry gives one.

  • Allervie Clinical Research - Birmingham- Site Number : 8401101

    Birmingham, Alabama

  • Cahaba Dermatology & Skin Health Center- Site Number : 8401066

    Birmingham, Alabama

  • Center for Dermatology and Plastic Surgery- Site Number : 8401119

    Scottsdale, Arizona

  • Scottsdale Clinical Trials- Site Number : 8401149

    Scottsdale, Arizona

  • Eclipse Clinical Research- Site Number : 8401158

    Tucson, Arizona

  • Arkansas Research Trials- Site Number : 8401244

    North Little Rock, Arkansas

  • Orange County Clinical Trials- Site Number : 8401271

    Anaheim, California

  • Encino Research Center- Site Number : 8401042

    Encino, California

  • First OC Dermatology- Site Number : 8401025

    Fountain Valley, California

  • Center for Dermatology Clinical Research- Site Number : 8401018

    Fremont, California

  • Marvel Clinical Research- Site Number : 8401102

    Huntington Beach, California

  • Sunwise Clinical Research - Lafayette- Site Number : 8401022

    Lafayette, California

  • Antelope Valley Clinical Trials- Site Number : 8401099

    Lancaster, California

  • Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027

    Lomita, California

  • Long Beach Clinical Trials- Site Number : 8401188

    Long Beach, California

  • Dermatology Research Associates- Site Number : 8401092

    Los Angeles, California

  • LA Universal Research Center- Site Number : 8401064

    Los Angeles, California

  • University Dermatology Trials- Site Number : 8401339

    Newport Beach, California

  • Cura Clinical Research - Oxnard- Site Number : 8401142

    Oxnard, California

  • Southern California Dermatology- Site Number : 8401043

    Santa Ana, California

  • Clinical Science Institute- Site Number : 8401028

    Santa Monica, California

  • Paradigm Clinical Research - Wheat Ridge- Site Number : 8401245

    Wheat Ridge, Colorado

  • UConn Health - Farmington- Site Number : 8401115

    Farmington, Connecticut

  • Encore Medical Research of Boynton Beach- Site Number : 8401030

    Boynton Beach, Florida

  • Pediatric Skin Research- Site Number : 8401198

    Coral Gables, Florida

  • St. Jude Clinical Research- Site Number : 8401287

    Doral, Florida

  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8401111

    Fort Myers, Florida

  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286

    Fort Myers, Florida

  • Direct Helpers Research Center- Site Number : 8401056

    Hialeah, Florida

  • Doral Medical Research - Hialeah- Site Number : 8401094

    Hialeah, Florida

  • Apex Clinical Research - Jacksonville- Site Number : 8401332

    Jacksonville, Florida

  • Clever Medical Research- Site Number : 8401160

    Miami, Florida

  • Miami Dermatology and Laser Research- Site Number : 8401086

    Miami, Florida

  • Medical Research Center of Miami II- Site Number : 8401019

    Miami, Florida

  • Acevedo Clinical Research Associates- Site Number : 8401088

    Miami, Florida

  • Future Care Solution - Miami- Site Number : 8401144

    Miami, Florida

  • Sanchez Clinical Research- Site Number : 8401095

    Miami, Florida

  • Florida International Research Center- Site Number : 8401091

    Miami, Florida

  • Savin Medical Group - Miami Lakes- Site Number : 8401085

    Miami Lakes, Florida

  • Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8401109

    Miami Lakes, Florida

Showing 40 of 392 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.